| Size | Price | Stock | Qty |
|---|---|---|---|
| 200 U |
|
||
| 500 U |
|
||
| 1000U |
|
||
| Other Sizes |
| Targets |
Recombinant DNase I targets DNA molecules, specifically catalyzing the endonucleolytic cleavage of phosphodiester bonds in DNA. It preferentially cleaves DNA at sites adjacent to pyrimidine nucleotides, producing oligonucleotides with 5'-phosphate termini. In biological systems, DNase I plays a critical role in limiting inflammatory responses by degrading extracellular DNA that can trigger immune activation, thereby helping to maintain homeostasis.
|
|---|---|
| ln Vitro |
In vitro, Recombinant DNase I (RNase-free) exhibits potent DNA-degrading activity. It is widely used in molecular biology applications to remove DNA contamination from RNA preparations, as it is free of RNase activity. The enzyme's activity can be measured by its ability to degrade DNA substrates, with optimal activity typically observed in the presence of divalent metal ions such as Mg2+ or Mn2+.
|
| ln Vivo |
In vivo, Recombinant DNase I plays an essential role in limiting inflammatory responses by degrading extracellular DNA that can activate inflammatory pathways, thereby contributing to the maintenance of homeostasis. Therapeutic applications of DNase I include the treatment of conditions associated with excessive DNA accumulation, such as cystic fibrosis, where it is used to reduce mucus viscosity by degrading DNA in airway secretions.
|
| Enzyme Assay |
Enzyme activity assays for Recombinant DNase I involve incubating the enzyme with a DNA substrate and measuring the generation of acid-soluble oligonucleotides or the decrease in DNA viscosity. Activity can be quantified spectrophotometrically by monitoring the increase in absorbance at 260 nm as DNA is hydrolyzed. One unit of DNase I activity is typically defined as the amount of enzyme that causes a 0.001 increase in absorbance per minute.
|
| Cell Assay |
Cell-based assays are not typically used for Recombinant DNase I, as its primary applications are in molecular biology and biochemical research. However, the enzyme can be studied in cellular models to evaluate its effects on extracellular DNA degradation and inflammation. Cells can be treated with DNase I to assess its impact on DNA-mediated immune responses.
|
| Animal Protocol |
In vivo animal protocols for Recombinant DNase I have been established for therapeutic applications. The enzyme is typically administered via inhalation or injection, and its efficacy is evaluated by measuring the reduction of DNA content in target tissues. In cystic fibrosis models, DNase I is administered to assess its effects on mucus clearance and lung function.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Recombinant DNase I depend on the route of administration. The enzyme has a molecular weight of approximately 31 kDa. When administered via inhalation, it acts locally in the airways with limited systemic absorption. The enzyme is typically stored at -20°C as a lyophilized powder and is stable under appropriate storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Recombinant DNase I are derived from its therapeutic applications. The enzyme is generally well-tolerated, with the most common side effects being mild throat irritation and voice alteration when administered via inhalation. As a research reagent, it is handled with standard laboratory precautions. The RNase-free formulation ensures that it does not degrade RNA.
|
| References | |
| Additional Infomation |
Recombinant DNase I (RNase-free) is a research-use-only biochemical reagent. It is widely used in molecular biology for the removal of DNA from RNA preparations, as it is free of RNase and protease activity. It is also used in diagnostic applications and therapeutic formulations. The enzyme is essential for limiting inflammatory responses and maintaining homeostasis.
|
| Molecular Formula |
C12H22N4O6
|
|---|---|
| Molecular Weight |
318.32628
|
| CAS # |
9003-98-9
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
100 g/mL at 20 °C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~43.48 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 5 mg/mL (Infinity mM) in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1414 mL | 15.7070 mL | 31.4139 mL | |
| 5 mM | 0.6283 mL | 3.1414 mL | 6.2828 mL | |
| 10 mM | 0.3141 mL | 1.5707 mL | 3.1414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
